

Treatment with Bisphosphonates

Coding Specifications

Codes required to document patient has multiple myeloma and a visit occurred:

A line item ICD-9-CM diagnosis for multiple myeloma and a CPT E/M service code are required to identify patients to be included in this measure.

All measure-specific coding should be reported ON THE SAME CLAIM.

Multiple myeloma line item ICD-9-CM diagnosis codes

- 203.00, 203.02 (multiple myeloma)

AND

CPT E/M service codes

- 99201, 99202, 99203, 99204, 99205 (office — new patient),
- 99212, 99213, 99214, 99215 (office — established patient),
- 99241, 99242, 99243, 99244, 99245 (outpatient consult)

Quality codes for this measure:

CPT II Code descriptors

(Data collection sheet should be used to determine appropriate code.)

- **CPT II 4100F:** Bisphosphonate therapy, intravenous, ordered or received
- **CPT II 4100F-1P:** Documentation of medical reason(s) for not prescribing bisphosphonates (eg, patients who do not have bone disease, patients with dental disease, patients with renal insufficiency)
- **CPT II 4100F-2P:** Documentation of patient reason(s) for not prescribing bisphosphonates
- **CPT II 4100F-8P:** Bisphosphonate therapy, intravenous, not ordered or received, reason not otherwise specified

These Physician Performance Measures (Measures) are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA), [on behalf of the Physician Consortium for Performance Improvement® (Consortium)] or the American Society of Hematology (ASH). Neither the AMA, ASH, Consortium nor its members shall be responsible for any use of the Measures.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

© 2006–7 American Medical Association and American Society of Hematology. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, ASH, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measures specifications is copyright 2007 American Medical Association. LOINC® copyright 2004 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004 College of American Pathologists (CAP). All Rights Reserved. Use of SNOMED CT® is only authorized within the United States.

PQRI 2009 Measure 69, Effective Date 01/01/2009

© 2006–7 American Medical Association and American Society of Hematology. All Rights Reserved.

CPT® copyright 2008 American Medical Association